Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C. Turner(Institute of Cancer Research), Alistair Ring(National Health Service), David Cameron(Corewell Health), Belinda Kingston(Breast Cancer Now), Michael Hubank(Royal Marsden Hospital), Ros Cutts(Institute of Cancer Research), Daniel Rea(University Hospitals Birmingham NHS Foundation Trust), Mark Tuthill(Oxford University Hospitals NHS Trust), Iain R. Macpherson(Beatson West of Scotland Cancer Centre), Heidrun Gevensleben(University Hospital Bonn), Rebecca Roylance(University College London Hospitals NHS Foundation Trust), Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Peter Stephens(Royal Devon & Exeter NHS Foundation Trust), Hannah Bye(Royal Marsden NHS Foundation Trust), Lucy Kilburn(Institute of Cancer Research), Sarah Kernaghan(Institute of Cancer Research), Laura Moretti(Institute of Cancer Research), Andrew Wardley(UK Research and Innovation), Claire Snowdon(Institute of Cancer Research), Richard D. Baird(Cancer Research UK), Matthew Winter(Weston Park Cancer Centre), Sue Martin(Institute of Cancer Research), Olga Oikonomidou(Edinburgh Cancer Research), Katie Wilkinson(Institute of Cancer Research), Jacinta Abraham(Velindre NHS Trust), Abeer M. Shaaban(Queen Elizabeth Hospital Birmingham), Katrina Randle(The Patients Association), Judith M. Bliss(Institute of Cancer Research)
Cited by 351
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k